Abstract:BACKGROUND:Amisulpride was introduced into China in 2010 as a second-generation atypical antipsychotic, while olanzapine has been on the market since 1999 as one of the leading treatments for schizophrenia in China. Since more Chinese patients are gaining access to amisulpride, the study aims to compare the efficacy, safety, and costs between amisulpride and olanzapine for schizophrenia treatment in China.METHODS:PubMed, Embase, the Cochrane library, China National Knowledge Infrastructure (CNKI) and WanFang database were systematically searched for randomized controlled trials (RCTs) up to July 2018. The Cochrane Risk of Bias tool was utilized to assess the quality of included studies. A meta-analysis was performed to compare the efficacy and safety of amisulpride and olanzapine, followed by a cost-minimization analysis using local drug and medical costs reported in China.RESULTS:Twenty RCTs with 2000 patients were included in the systematic review. There were no significant differences between amisulpride and olanzapine on efficacy measures based on scores from the Positive and Negative Syndrome Scale, the Scale for the Assessment of Negative Symptoms, the Brief Psychiatric Rating Scale and the Clinical Global Impressions-Severity or Improvement. For safety outcomes, amisulpride was associated with lower fasting blood glucose and less abnormal liver functions as well as significantly lower risks of weight gain, constipation, and somnolence; olanzapine was associated with significantly lower risks of insomnia and lactation/amenorrhea/sexual hormone disorder. No significant differences were found in risks of extrapyramidal symptoms (EPS), tremor, akathisia, abnormal corrected QT interval. Cost-minimization analysis showed that amisulpride was likely to be a cost-saving alternative in China, with potential savings of 1358 Chinese Yuan (CNY) per patient for a three-month schizophrenia treatment compared with olanzapine.CONCLUSION:As the first meta-analysis and cost-minimization analysis comparing the efficacy, safety and cost of amisulpride and olanzapine within a Chinese setting, the study suggests that amisulpride may be an effective, well-tolerated, and cost-saving antipsychotic drug alternative in China.

Comparative Study of Amisulpride vs . Olanzapine for the Treatment of Schizophrenia

A controlled trial of olanzapine and fluoxetine in treatment of negative symptoms of schizophrenia

Efficacy and safety of olanzapine combined with fluoxetine in treatment of depression

A double blinded multicenter clinical trial for evaluating the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia

Comparison the clinical effects and safety of amisulpride and risperidone in the treatment of schizophrenia

The Effectiveness and Safety of Amisulpride in Chinese Patients with Schizophrenia Who Switch from Risperidone or Olanzapine: a Subgroup Analysis of the ESCAPE Study.

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia A Randomized, Double-Blind, Multicenter Study

Comparative Efficacy and Safety Between Amisulpride and Olanzapine in Schizophrenia Treatment and a Cost Analysis in China: a Systematic Review, Meta-Analysis, and Cost-Minimization Analysis.

The efficacy and safety of amisulpride in the treatment of acute exacerbation patients with schizophrenia

Efficacy and quality of life comparative study of amisulpride and sulpride in treatment of first-episode schizophrenia

Comparative Study Between Aripiprazole and Chlorpromazine in Treatment of Schizophrenia

Comparative Cost-Effectiveness of Amisulpride and Olanzapine in the Treatment of Schizophrenia in China.

The Effectiveness And Safety Of Amisulpride In Chinese Patients With Schizophrenia: An 8-Week, Prospective, Open-Label, Multicenter, Single-Arm Study

The Efficacy and Adverse Effects of Haloperidol and Olanzapine: a Randomized Controlled Study.

A controlled study of Ziprasidone, Risperidone and Haloperidol in the treatment of the acute phrase of schizophrenia

A Study of the Efficacy and Safety of Olanzapine in the Treatment of Schizophrenia

Double-blind,double-dummy and randomized controlled study of aripiprazole in the treatment of acute schizophrenia

Comparison of Curative Effect and Safety of Olanzapine and Risperidone in the Treatment of Female Schizophrenia

Effectiveness of Amisulpride in Chinese Patients with Predominantly Negative Symptoms of Schizophrenia: a Subanalysis of the ESCAPE Study

Cost-Effectiveness Analysis of Amisulpride and Olanzapine for Patients with Schizophrenia in China